PULMOBIOMED is addressing the failings of current lung tests, which are expensive, infrequent, and invasive. Their so-called "clinically proven" solution claims to offer non-invasive liquid samples from deep within the lung, promising affordable tests for lung diseases. They assert that their product can empower clinicians to diagnose and treat conditions like lung cancer and infections, even though there's limited evidence to support these claims. With a few customers in the USA and Australia, and vague partnerships in the EU, PULMOBIOMED hopes to disrupt the asthma diagnostics market by introducing what they call a comprehensive diagnostic test for asthma, despite the skepticism around their capabilities.
days to go:
Extended
investment:
£295,000
Carocell Bio is innovating by developing patented anti-inflammatory peptides delivered via nanoparticles to address severe inflammatory conditions such as atopic dermatitis. Their primary peptide, JEL0305, not only halts inflammation but also prevents its initiation, as evidenced by its effectiveness in reducing inflammation in human AD biopsies and burn tissue. With AD impacting a substantial population and costing $21 billion yearly for unsafe treatments, Carocell Bio's safer peptide remedy has the potential to avert AD recurrence. Additionally, their pioneering approach to skin-related inflammation involves topical peptide products that target mitogen-activated protein kinase (MAPK), a crucial element in inflammation. This breakthrough offers promise for managing and forestalling AD and mitigating skin aging.
days to go:
Extended
investment:
Withheld
Optimise BP, the debut product by Optimise Health, introduces an innovative digital solution that offers secure and efficient semi-automated blood pressure management within primary care, focusing on hypertension. This advancement is projected to lead to substantial appointment savings in the range of millions.
days to go:
TBC
investment:
£127,001
MGN Builders Merchants is a well-established, profitable, and a fast-growing builders merchants and skip hire based in London and Essex. It offers same or next day delivery on thousands of building products kept in stock at all times. Having served 50,000+ customers in 2018 (81k EBITDA), the company's client base includes small to medium-sized companies, private developers and DIY customers. In the last three years, the company has trebled its revenue from £2.5m in 2016 to £7m by January 2019, achieving an almost 100% sales increase YoY. MGN is raising funding to accelerate its rapid growth plans, expand its team, start selling online, and launch concrete delivery service to capture UK's £34bn construction supplied wholesale market.
days to go:
Expired
investment:
£114,260
Her.9 is a Direct-To-Consumer (DTC) female technology brand that caters to the needs of women during pregnancy. It cites research arguing that up to 40% of women taking prenatal vitamins may not be able to absorb the folic acid within the UK’s leading pregnancy brand. Her.9 aims to resolve this by employing DUOCAP technology. The company asserts that DUOCAP is a capsule-in-capsule delivery system which contains solubilised prebiotics in the outer capsule and probiotics in the inner capsule. The prebiotic releases immediately and the probiotic releases later allowing for targeted supplement delivery in the body. The prenatal supplements market is set to be worth $56 billion globally by 2024. Her.9 aims to be a notable contender in this segment. The company is raising investment to build its already established partnerships and execute its marketing strategy effectively.
days to go:
Expired
investment:
£215,946
Liquid supplements are a faster acting and a more efficient way for the body to absorb key active ingredients than taking pills. Our scientists have developed formulations involving leading active ingredients such as collagen in order to create the perfect wellness solution in every bottle. Each LQ bottle is packed full of 9 or more active ingredients all in one easy to drink, daily 50 m bottle.
days to go:
Expired
investment:
£355,000
Doctaly is the brand new healthcare platform providing the quickest way to find and book an affordable, face-to-face, same day GP appointment. Choose from their trusted private doctors, at a convenient time and location from just £39.99.
days to go:
Expired
investment:
£807,580
Carnot is developing hydrogen engines with key components manufactured from ceramics able to withstand fuel combustion temperatures, eliminating the need for cooling systems and doubling the efficiencies of modern engines. The company argues that modern engines waste on average one-third of fuel energy to cool systems that stop metallic components from melting. Carnot claims that its engines eliminate this waste doubling efficiency, halve fuel costs and CO2 and achieve net-zero operation by operating on biofuels and hydrogen benefiting the long haul transport, marine and primary off-grid power markets. Carnot has raised over £600,000 including a pre-seed round in 2020 for £357,000 at a pre-money valuation of £2 million, a £300,000 Innovate UK grant and another £300,000 Eureka Eurostar’s grant. Carnot has a 5-year, 3-phase exit strategy and will begin licensing its IP at the end of 2023 at which point it will begin generating revenue. It will eventually look for acquisition from one of its manufacturing partners in 2025 after demonstrating industry acceptance of its technology.
days to go:
Expired
investment:
£262,500
We created FlyFit with the aim to change the way people travel. Air travel can be stressful, lonely, and unhealthy. On top of this, with average layovers of 2+ hours, flight delays, and hours waiting in security, there is too much unproductive time in airports with limited healthy options to choose from.
days to go:
Expired
investment:
£500,060
Viritech is a clean technology engineering company that is using F1-derived engineering to develop hydrogen powertrain solutions and related technologies for the automotive, aerospace, marine and distributed power industries. Viritech asserts that the Hydrogen Council forecasts that hydrogen will meet 18% of global energy demand by 2050. It aims to capture this demand through its technologies. Viritech argues that its location in MIRA Technology Park allows it access to R&D facilities used by many of the world's major automotive manufacturers, allowing it to scale its resources to meet the demands of every type of project. Viritech will use the investment to produce test hydrogen tanks, build the Apricale hypercar, complete designs for a Heavy Goods Vehicle (HGV), Sport Utility Vehicle (SUV) and a power generator, plan a larger raise and listing on AQuis Stock Exchange (AQSE) in 2022, and eventually commercialise its technology with its partner.
days to go:
Expired
investment:
£726,807
